{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:23:47Z","timestamp":1770531827445,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ono Pharmaceutical Co., Ltd., Osaka, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tirabrutinib is a Bruton\u2019s tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib at a dose of 160\u00a0mg, 320\u00a0mg, or 480\u00a0mg once daily, or 300\u00a0mg twice daily (<jats:italic>N<\/jats:italic>\u2009=\u20093, 3, 4, and 7, respectively). Three patients continued tirabrutinib until study completion (November 30, 2020). Adverse events (AEs) occurred in all 17 patients, with Grade 3\u20134 AEs in 8 (47.1%), serious AEs in 7 (41.2%), drug-related AEs in 16 (94.1%), and Grade 3\u20134 drug-related AEs in 6 (35.3%). Drug-related AEs reported in 3 or more patients were rash, vomiting, neutropenia, arthralgia, and malaise. One additional serious AE (benign neoplasm of the lung, unrelated to tirabrutinib) occurred after the previous data cutoff (January 4, 2018). Tirabrutinib administration and response assessment were continued for over 4\u00a0years in 4 patients. The overall response rate was 76.5% (13\/17 patients). The median (range) time to response and duration of response were 0.9 (0.9\u20135.9) months and 2.59 (0.08\u20135.45) years, respectively. These findings demonstrate the long-term safety and efficacy of tirabrutinib in Japanese patients with B-cell malignancies.<\/jats:p><jats:p>Clinical trial registration: JapicCTI-142682 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.jp\/\">http:\/\/www.clinicaltrials.jp\/<\/jats:ext-link>).<\/jats:p>","DOI":"10.1007\/s12185-022-03514-6","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T05:02:46Z","timestamp":1672203766000},"page":"553-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4679-0656","authenticated-orcid":false,"given":"Wataru","family":"Munakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ogiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arata","family":"Aoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hatsumichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"3514_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00748.x","volume":"228","author":"T Kurosaki","year":"2009","unstructured":"Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev. 2009;228:132\u201348.","journal-title":"Immunol Rev"},{"key":"3514_CR2","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","volume":"19","author":"Y Qiu","year":"2000","unstructured":"Qiu Y, Kung HJ. Signaling network of the BTK family kinases. Oncogene. 2000;19:5651\u201361.","journal-title":"Oncogene"},{"key":"3514_CR3","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1002\/eji.1830241228","volume":"24","author":"HC Genevier","year":"1994","unstructured":"Genevier HC, Hinshelwood S, Gaspar HB, Rigley KP, Brown D, Saeland S, et al. Expression of Bruton\u2019s tyrosine kinase protein within the B cell lineage. Eur J Immunol. 1994;24:3100\u20135.","journal-title":"Eur J Immunol"},{"key":"3514_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1358\/dot.2021.57.4.3264113","volume":"57","author":"W Munakata","year":"2021","unstructured":"Munakata W, Tobinai K. Tirabrutinib hydrochloride for B-cell lymphomas. Drugs Today (Barc). 2021;57:277\u201389.","journal-title":"Drugs Today (Barc)"},{"key":"3514_CR5","unstructured":"Janssen\/Pharmacyclics LLC. IMBRUVICA\u00ae (ibrutinib) capsules 140\u00a0mg. Interview form, Sep 2021, 10th Edition. Available at: https:\/\/mc-e2ce8b00-afab-4ff9-ae22-349570-cdn-endpoint.azureedge.net\/-\/media\/Project\/Janssen\/Japan\/Product\/ibr\/pdf\/ibr_if.pdf?rev=5ec3a5e966354607a1e0042785112f2c&download=1. Accessed Mar 1, 2022 (in Japanese)."},{"key":"3514_CR6","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1158\/1078-0432.CCR-19-3504","volume":"26","author":"AV Danilov","year":"2020","unstructured":"Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, et al. Phase Ib study of tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2020;26:2810\u20138.","journal-title":"Clin Cancer Res"},{"key":"3514_CR7","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.13983","volume":"110","author":"W Munakata","year":"2019","unstructured":"Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, et al. Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019;110:1686\u201394.","journal-title":"Cancer Sci"},{"key":"3514_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23:122\u201333.","journal-title":"Neuro Oncol"},{"key":"3514_CR9","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/s41375-019-0658-7","volume":"34","author":"SA Rule","year":"2020","unstructured":"Rule SA, Cartron G, Fegan C, Morschhauser F, Han L, Mitra S, et al. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton\u2019s tyrosine kinase inhibitor tirabrutinib (GS\/ONO-4059). Leukemia. 2020;34:1458\u201361.","journal-title":"Leukemia"},{"key":"3514_CR10","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1111\/cas.14561","volume":"111","author":"N Sekiguchi","year":"2020","unstructured":"Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Cancer Sci. 2020;111:3327\u201337.","journal-title":"Cancer Sci"},{"key":"3514_CR11","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2017-02-765115","volume":"129","author":"HS Walter","year":"2017","unstructured":"Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, et al. Long-term follow-up of patients with CLL treated with the selective Bruton\u2019s tyrosine kinase inhibitor ONO\/GS-4059. Blood. 2017;129:2808\u201310.","journal-title":"Blood"},{"key":"3514_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127:411\u20139.","journal-title":"Blood"},{"key":"3514_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32\u201342.","journal-title":"N Engl J Med"},{"key":"3514_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"3514_CR15","unstructured":"ONO Pharmaceutical Co., Ltd. VELEXBRU\u00ae (tirabrutinib) tablets 80\u00a0mg. Interview form, revised Feb 2022, 5th Edition. Available at: https:\/\/www.ono-oncology.jp\/medical\/products\/velexbru\/drug-info. Accessed Mar 1, 2021 (in Japanese)."},{"key":"3514_CR16","unstructured":"ONO Pharmaceutical Co., Ltd. Velexbru\u00ae Tablet 80\u00a0mg, a BTK inhibitor, approved in South Korea for treatment of recurrent or refractory B-cell primary central nervous system lymphoma. Press release, Nov 8, 2021. Available at: https:\/\/www.ono-pharma.com\/news\/20211108.html. Accessed Mar 1, 2021."},{"key":"3514_CR17","unstructured":"Velexbru\u00ae Tablet 80\u00a0mg, a BTK inhibitor, approved in Taiwan for the treatment of recurrent or refractory B-cell primary central nervous system lymphoma. Press release, Feb 21, 2022. Available at: https:\/\/www.ono-pharma.com\/news\/20220221.html. Accessed Mar 1, 2022."},{"key":"3514_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11899-020-00576-3","volume":"15","author":"M Lasica","year":"2020","unstructured":"Lasica M, Tam CS. Management of ibrutinib toxicities: a practical guide. Curr Hematol Malig Rep. 2020;15:177\u201386.","journal-title":"Curr Hematol Malig Rep"},{"key":"3514_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80\u20137.","journal-title":"JAMA Oncol"},{"key":"3514_CR20","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874\u20139.","journal-title":"Haematologica"},{"key":"3514_CR21","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.3747\/co.26.4345","volume":"26","author":"C Owen","year":"2019","unstructured":"Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26:e233\u201340.","journal-title":"Curr Oncol"},{"key":"3514_CR22","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CSL Tam","year":"2020","unstructured":"Tam CSL, Opat S, D\u2019Sa S, Jurczak W, Lee H-P, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136:2038\u201350.","journal-title":"Blood"},{"key":"3514_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739\u201345.","journal-title":"Blood"},{"key":"3514_CR24","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI sponsored international working group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"3514_CR25","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"3514_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/bjh.12102","volume":"160","author":"RG Owen","year":"2013","unstructured":"Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the 6th international workshop. Br J Haematol. 2013;160:171\u20136.","journal-title":"Br J Haematol"},{"key":"3514_CR27","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","volume":"133","author":"JC Byrd","year":"2019","unstructured":"Byrd JC, Hillmen P, O\u2019Brien S, Flinn IW, Burger JA, Blum KA, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133:2031\u201342.","journal-title":"Blood"},{"key":"3514_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","volume":"100","author":"WJ Archibald","year":"2021","unstructured":"Archibald WJ, Rabe KG, Kabat BF, Herrmann J, Ding W, Kay NE, et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021;100:143\u201355.","journal-title":"Ann Hematol"},{"key":"3514_CR29","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","volume":"14","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PLoS ONE. 2019;14:e0211228.","journal-title":"PLoS ONE"},{"key":"3514_CR30","doi-asserted-by":"publisher","first-page":"e1916326","DOI":"10.1001\/jamanetworkopen.2019.16326","volume":"2","author":"LE Roeker","year":"2019","unstructured":"Roeker LE, Sarraf Yazdy M, Rhodes J, Goodfriend J, Narkhede M, Carver J, et al. Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia. JAMA Netw Open. 2019;2:e1916326.","journal-title":"JAMA Netw Open"},{"key":"3514_CR31","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"3514_CR32","doi-asserted-by":"publisher","first-page":"668162","DOI":"10.3389\/fonc.2021.668162","volume":"11","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Wierda WG. Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Front Oncol. 2021;11:668162.","journal-title":"Front Oncol"},{"key":"3514_CR33","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9:630942.","journal-title":"Front Cell Dev Biol"},{"key":"3514_CR34","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/cas.14886","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, et al. Safety and antitumor activity of acalabrutinib for relapsed\/refractory B-cell malignancies: a Japanese phase I study. Cancer Sci. 2021;112:2405\u201315.","journal-title":"Cancer Sci"},{"key":"3514_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","volume":"3","author":"FT Awan","year":"2019","unstructured":"Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019;3:1553\u201362.","journal-title":"Blood Adv"},{"key":"3514_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1182\/blood.2019003715","volume":"136","author":"C Sun","year":"2020","unstructured":"Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136:93\u2013105.","journal-title":"Blood"},{"key":"3514_CR37","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res. 2020;26:4216\u201324.","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03514-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03514-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03514-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T08:56:33Z","timestamp":1680166593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03514-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3514"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03514-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"11 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wataru Munakata reports research funds from Ono Pharmaceutical Co., Ltd. Kiyoshi Ando reports research funds from Celgene K.K., Novartis Pharma K.K., and Astellas Pharma Inc.; and scholarship endowments from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Kyowa Kirin Co., Ltd. Masahiro Yokoyama reports acting as a medical adviser for Chugai Pharmaceutical Co., Ltd. Noriko Fukuhara reports lecture fees, honoraria, or other personal fees from SymBio Pharmaceuticals Ltd., Chugai Pharmaceutical Co., Ltd., and HUYA Bioscience International LLC; and research funds from Incyte Japan, Genmab K.K., Celgene K.K., Chugai Pharmaceutical Co., Ltd., and Bayer Yakuhin, Ltd. Kazuhito Yamamoto reports lecture fees, honoraria, or other personal fees from AbbVie GK, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., Micron Inc., and Takeda Pharmaceutical Co., Ltd.; and research funds from Symbio Pharmaceuticals Ltd. and Yakult Honsha Co., Ltd. Suguru Fukuhara reports research funds from Chugai Pharmaceutical Co., Ltd. Ken Ohmachi has nothing to report. Yuko Mishima reports holding shares or share options in Chugai Pharmaceutical Co., Ltd.; and research funds from Takeda Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Satoshi Ichikawa reports research funds from AstraZeneca K.K. and BeiGene Japan. Daisuke Ogiya has nothing to report. Arata Aoi is an employee of Ono Pharma USA, Inc. Masahiro Hatsumichi is an employee of Ono Pharmaceutical Co., Ltd. Kensei Tobinai reports lecture fees, honoraria, or other personal fees from Zenyaku Kogyo Co., Ltd., HUYA Bioscience International LLC, Daiichi Sankyo Co., Ltd., and SymBio Pharmaceutical Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}